Cutaneous Oncology and Oncodermatology
An Introduction to Cutaneous Oncology and Oncodermatology
Dermato-oncology is a rapidly evolving branch of dermatology focusing on the management, prevention and treatment of both prevalent and uncommon types of malignant skin tumours. These encompass a wide spectrum of skin tumours, from melanoma and epithelial skin cancers to tumours arising from neuroendocrine and lymphoid origins. The rise in the incidence of melanoma and other skin cancers has been propelled by population ageing. The integration of advanced diagnostic tools such as dermatoscopy and innovative therapies for advanced melanoma and nonmelanoma skin cancers has led to remarkable transformations in the structure of patient management within clinical environments.
Our supporting partners do not constitute an endorsement of the content on this page.
From pruritus and burn scars to cutaneous neurofibromas, Prof. Ashraf Badawi explores some of the new directions for lasers and energy-based devices discussed at this years EADV congress.
RLS-1496 1% cream (Rubedo Life Sciences, CA, USA) is an investigational senotherapeutic treatment that selectively and potently inhibits the antioxidant enzyme glutathione peroxidase 4 (GPX4). It aims to target senescent cells, potentially offering a new approach to treating AK.2 Results from a phase 1b/2a, multicenter, open-label clinical study of RLS-1496 1% cream were presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Congress 2026.
Meet the dermatologists redefining the future of practice, research, and technology Meet the innovators shaping the future of dermatology The touchDERMATOLOGY Future Leaders 2026 have been nominated and selected to recognize the rising stars shaping the future of across the field ...
We are delighted to announce Dr Zoë Venables as a touchDERMATOLOGY Future Leader 2026. Dr Zoë Venables is a Consultant Dermatologist and Clinical Associate Professor at the University of East Anglia, Norwich, UK. She is Clinical Lead for Dermatology at NHS ...
We are delighted to welcome Dr Brittany Dulmage as a touchDERMATOLOGY Future Leader 2026. Brittany Dulmage, MD, FAAD, is a US board-certified dermatologist and Associate Professor of Dermatology at The Ohio State University (OSU) Wexner Medical Center in Columbus, OH, USA. ...
We are delighted to announce Dr Anastasiya Muntyanu as a touchDERMATOLOGY Future Leader 2026. Based in Toronto, Canada, Anastasiya Muntyanu, MD, PhD, FRCPC, FAAD, is a Canadian and US board-certified dermatologist practising at the Women's College Hospital and the Princess Margaret ...
We are delighted to announce Dr Martyna Sławińska as a touchDERMATOLOGY Future Leader 2026. Dr Martyna Sławińska is advancing the field of dermatology through her work on non-invasive skin imaging and its application beyond skin cancer. Based ...
From adjuvant immunotherapy in Merkel cell carcinoma to cellular therapy in advanced melanoma, late-breaking ASCO data offer new insights into evolving treatment strategies for difficult-to-treat skin cancers.
Join us as leading experts discuss key data and perspectives from the late-breaking sessions at this year’s AAD meeting This March, experts from around the world gathered in Denver, Colorado, for the 2026 American Academy of Dermatology (AAD) Annual Meeting. ...
New early-phase data on PH-762 presented at AAD 2026 have highlighted the promise of directed intratumoural immunotherapy in cutaneous carcinomas. In this Q&A, Dr Mary Spellman shares the key findings from the escalating-dose study and reflects on their potential implications for future development.
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
Recent studies have identified the PI3K/mTOR pathway as a significant driver of actinic keratosis development and progression. Targeting this pathway, bimiralisib is an investigational selective pan-PI3K/mTOR inhibitor formulated as a topical treatment, designed to reduce AK lesion proliferation while minimising systemic adverse events.
This year, we are celebrating our inaugural touchDERMATOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform dermatology in the years to come. Representing a diverse range of expertise from across the globe, these highly accomplished clinicians are among the brightest minds shaping the future of dermatology. We had the pleasure of learning about their unique career journeys, motivations, and the inspirations that have guided their paths. They also shared their perspectives on the most exciting developments in dermatology today, along with their hopes for the future of the field. Congratulations to all our touchDERMATOLOGY Future Leaders, and thank you for sharing your stories, insights and ambitions with us.
Dr Tashmeeta Ahad is helping to push the boundaries of modern dermatology. Based in Vancouver, she is a Clinical Assistant Professor at the University of British Columbia and a clinician-scientist at the Photomedicine Institute, where her work spans photosensitivity disorders, laser and phototherapy, and innovative optical biopsy techniques for skin cancer monitoring. In this Future Leader 2025 Q&A, Dr Ahad shares how her global training journey, early mentors, and the visual complexity of dermatology have shaped her career—and why imaging technologies are opening new possibilities for patient care.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
